AU2023208031A1 - Designed cytokine compositions and methods of use - Google Patents

Designed cytokine compositions and methods of use Download PDF

Info

Publication number
AU2023208031A1
AU2023208031A1 AU2023208031A AU2023208031A AU2023208031A1 AU 2023208031 A1 AU2023208031 A1 AU 2023208031A1 AU 2023208031 A AU2023208031 A AU 2023208031A AU 2023208031 A AU2023208031 A AU 2023208031A AU 2023208031 A1 AU2023208031 A1 AU 2023208031A1
Authority
AU
Australia
Prior art keywords
cell
designed
cytokine
sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023208031A
Other languages
English (en)
Inventor
Scott BOYKEN
Thaddeus M. DAVENPORT
Marc Lajoie
Howell MOFFETT
Andrew Howen NG
Paul Joseph SAMPLE
Brian WEITZNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Outpace Bio Inc
Original Assignee
Outpace Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Outpace Bio Inc filed Critical Outpace Bio Inc
Publication of AU2023208031A1 publication Critical patent/AU2023208031A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2023208031A 2022-01-11 2023-01-11 Designed cytokine compositions and methods of use Pending AU2023208031A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263298623P 2022-01-11 2022-01-11
US63/298,623 2022-01-11
US202363479178P 2023-01-09 2023-01-09
US202363479177P 2023-01-09 2023-01-09
US202363479176P 2023-01-09 2023-01-09
US63/479,177 2023-01-09
US63/479,176 2023-01-09
US63/479,178 2023-01-09
PCT/US2023/060508 WO2023137346A2 (en) 2022-01-11 2023-01-11 Designed cytokine compositions and methods of use

Publications (1)

Publication Number Publication Date
AU2023208031A1 true AU2023208031A1 (en) 2024-08-29

Family

ID=87279672

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023208031A Pending AU2023208031A1 (en) 2022-01-11 2023-01-11 Designed cytokine compositions and methods of use

Country Status (10)

Country Link
US (1) US20250223330A1 (https=)
EP (1) EP4463469A4 (https=)
JP (1) JP2025502205A (https=)
KR (1) KR20240164594A (https=)
CN (1) CN119053616A (https=)
AU (1) AU2023208031A1 (https=)
CA (1) CA3248134A1 (https=)
IL (1) IL314226A (https=)
MX (1) MX2024008642A (https=)
WO (1) WO2023137346A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL325764A (en) * 2023-07-13 2026-03-01 Outpace Bio Inc Designed compositions of interleukin-2 cytokine and methods of use
WO2025212606A1 (en) * 2024-04-01 2025-10-09 Bio-Techne Corporation Synthetic il-2 polypeptides and conjugates, compositions, and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210025522A (ko) * 2018-06-25 2021-03-09 유니버시티 오브 워싱톤 강력하고 선택적인 인터루킨 모방체의 드 노보 디자인
MX2021000801A (es) * 2018-07-24 2021-04-12 BioNTech SE Agonistas de il2.
CN118510795A (zh) * 2022-01-07 2024-08-16 苏州克睿基因生物科技有限公司 新型白介素-2多肽

Also Published As

Publication number Publication date
US20250223330A1 (en) 2025-07-10
KR20240164594A (ko) 2024-11-19
IL314226A (en) 2024-09-01
CA3248134A1 (en) 2023-07-20
MX2024008642A (es) 2024-09-23
EP4463469A2 (en) 2024-11-20
EP4463469A4 (en) 2026-01-14
WO2023137346A2 (en) 2023-07-20
JP2025502205A (ja) 2025-01-24
CN119053616A (zh) 2024-11-29
WO2023137346A3 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
US11400133B2 (en) Receptor-based antagonists of the programmed cell death 1 (PD-1) pathway
JP6783797B2 (ja) 抗がん融合ポリペプチド
KR102653906B1 (ko) 편향된 il2 뮤테인 방법 및 조성물
JP6041799B2 (ja) Ｔｒａｉｌｒ２特異的多量体足場
KR20220016945A (ko) 다중특이적 단백질
CN111511911A (zh) 表达特异性地识别人间皮素的细胞表面分子、il-7和ccl19的免疫活性细胞
CA3150226A1 (en) Chimeric orthogonal receptor proteins and methods of use
WO2022169913A2 (en) Synthetic degrader system for targeted protein degradation
EP4463469A2 (en) Designed cytokine compositions and methods of use
US20230027899A1 (en) Cd122 with altered icd stat signaling
US20230374454A1 (en) Human immune cells genomically modified to express orthogonal receptors
WO2023081718A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
JP2026041861A (ja) Ｉｌ２オルソログおよび使用法
KR20250024838A (ko) Kras g12v 돌연변이 폴리펩티드를 표적화하는 t 세포 수용체 및 이의 용도
KR20220143939A (ko) G12v 돌연변이를 갖는 ras에 대한 hla 클래스 ii-제한된 t 세포 수용체
WO2025015322A1 (en) Designed interleukin-2 cytokine compositions and methods for use
AU2024340744A1 (en) Anti-mesothelin chimeric antigen receptors and methods of use
KR20240004453A (ko) 변형된 과립구 집락-자극 인자(g-csf) 및 이에 결합하는 키메라 사이토카인 수용체
EP3749349A1 (en) Mutant idh1 specific t cell receptor
TW202434618A (zh) 經設計之細胞激素組合物及使用方法
WO2025207624A1 (en) Compositions and methods useful in the treatment of autoimmune disease
JP2024529340A (ja) 新生物疾患の細胞療法に使用するための方法および組成物
WO2023150649A2 (en) Synthetic degrader system for targeted protein degradation